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Abstract
Background: Protein profiling with surface-enhanced laser desorption-ionisation time-of-flight
mass spectrometry (SELDI-TOF MS) is a promising approach for biomarker discovery. Some
candidate biomarkers have been identified using SELDI-TOF, but validation of these can be
challenging because of technical parameters that effect reproducibility. Here we describe steps to
improve the reproducibility of peak detection.
Methods:  SELDI-TOF mass spectrometry was performed using a system manufactured by
Ciphergen Biosystems along with their ProteinChip System. Serum from 10 donors was pooled and
used for all experiments. Serum was fractionated with Expression Difference Mapping kit-Serum
Fractionation from the same company and applied to three different ProteinChips. The
fractionations were run over a one month period to examine the contribution of sample batch and
time to peak detection variability. Spectra were processed and peaks detected using the Ciphergen
Express software and variance measured.
Results: Experimental parameters specific to the serum fraction and ProteinChip, including spot
protocols (laser intensity and detector sensitivity) were optimized to decrease peak detection
variance. Optimal instrument settings, regular calibration along with controlled sample handling and
processing nearly doubled the number of peaks detected and decreased intensity variance.
Conclusion: This report assesses the variation across fractionated sera processed over a one-
month period. The optimizations reported decreased the variance and increased the number of
peaks detected.
Background
The SELDI-TOF mass spectroscopy platform was designed
for high-throughput protein profiling and biomarker dis-
covery. The resolution of SELDI-TOF has been improved
by incorporating fractionation and a variety of affinity
capture techniques [1,2]. Still there are sources of techni-
cal and biologic variation which make reproducing and
validating potential biomarkers challenging [3-6]. Further
refinements to the technique are necessary to ensure that
the variability in mass spectra is due to biology and to
minimize systematic biases from non-disease associated
factors [7-9].
Validation of disease biomarkers relies on optimized and
reproducible laboratory methods. The automation of the
SELDI-TOF platform and the standardization of parame-
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ters for analysis have resulted in good intra- and inter-lab-
oratory correlation and relatively reproducible results
[2,3,8]. However, there is still a need to identify the
sources of variation and determine how to reduce the var-
iation to make the SELDI-TOF platform reliable and
reproducible. We examined some the front-end steps,
including sample handling and preparation that occur
during SELDI-TOF. Fine-tune adjustments of laser inten-
sity and detector sensitivity for each chip type and each
fraction coupled with spot-to-spot correction increased
peak detection and significantly decreased the intensity
coefficient of variation (CV). These further refinements to
the SELDI-TOF platform will enhance biomarker identifi-
cation and validation efforts.
Results
We identified the ProteinChips and fractions with the
most informative mass spectra (Table 1), for use in our
comparisons. Generally, Fraction 2 (F2) was very sparse in
mass peaks on all chips and F5 had a small number of
peaks, not consistently detected and generally of a lower
quality. Spectra included in analyses had normalization
factors <2 standard deviations (SD) from the mean. Spec-
tra with normalization factors greater than the mean ±
2SD tended to be poor quality spectra, either with heavy
matrix noise and no peaks, or poor peak intensities. This
was chosen as the cut-off value for spectral exclusion. The
minimum peak threshold setting for peak detection was
set at 80% for both experiments, insuring the minor vari-
ations in peak patterns seen in Exp 1 were kept in the data-
sets.
Table 2 presents results comparing the effect of experi-
mental conditions on spectra quality across all batches.
These included laser intensity and detector sensitivity
adjustments to spot protocols for each fraction, auto-
mated applications and defined drying steps. Fewer spec-
tra were excluded in Exp 2 with several ProteinChip/
Fraction combinations having no excluded spectra. The
largest impact, as assessed by number of spectra removed,
appears to be on the CM10 ProteinChip surface (Table 2).
Peak selection criteria requested that each peak needed to
be present in 80% of spectra to be included in analysis.
The number of peaks detected almost doubled in Exp 2
and the CVs for peak intensities improved substantially
(Table 2). The quality of the peaks did not improve sub-
stantially in term of signal-to-noise ratio (S/N) and reso-
lution, but the intensity of the peaks globally increased,
and this contributed probably to better peak detection.
The weak cation exchange ProteinChip (CM10), using
low stringency (LS) buffers (CM10-LS), under Exp 2 con-
ditions appeared to give the least variant, most complex
spectra of all chip surfaces, as determined by number of
peaks detected and range of peak intensity CVs (Table 2).
We have used peak number as a reflection of spectral com-
plexity. Other parameters can be used to define this, such
as S/N ratio, signal height to valley depth.
To determine the reproducibility between the 3 batches in
which sera were run we looked for statistical differences in
peak intensities between batches using a Kruskal-Wallis
non parametric test, adjusted for multiple testing by boot-
strapping. We determined the number of peaks in each
batch that were statistically different (p < 0.01). The
results are presented in Table 2. Four ProteinChip/Frac-
tions in Exp 2 showed >40% of peaks determined on a
single quality control (QC) serum that were statistically
different across the batches (Table 2). In general, the
CM10-LS fractions showed the lowest batch-to-batch var-
iation.
Discussion
Recent advances have been made in mass spectrometry to
achieve high throughput separation and analysis of pro-
teins and peptides with good mass accuracy and resolu-
tion. One of the most difficult challenges of the method is
the reproducibility of the data over time and between lab-
oratories. Several studies have addressed this issue look-
ing at the impact of preanalytical variables like patient
preparation [4], blood sample processing [3], and stand-
ardized analytical conditions [8,9]. The main thrust of this
study was to examine the effects of spot protocol optimi-
zation on spectral quality as determined by number of
peaks and signal intensity CVs on a QC sample. There are
several laboratory considerations that have previously
been reported and were implemented in this study. For
example it is widely recommended that sample loading be
handled through an automated liquid handling system
[6,10], and that they be randomly loaded on the Protein-
Chips [11]. We used the Biomek 2000 Automation Work-
station for these purposes. EAM was applied in two
smaller volumes with a constant drying time before the
EAM application to increase the number of peaks [6]. Rea-
gent variability was minimized by using reagents from the
same manufacturing lot [11] and the possible effects of
freezing and thawing and length of time in storage [12]
was considered for the serum and fractionated products.
Exp 1 details our first fractionation/profiling methods and
Exp 2 our fine-tuning of the initial methodologies. EAM
Table 1: Fractions and ProteinChips considered having sufficient 
complexity for the analysis.
ProteinChip Fractions used in analysis
IMAC F1 F3 F4 F6
H50 F1 F3 F4 F6
C M 1 0 - L S F 1F 3 F 4F 5F6
CM10-HS F3 F4
Bold – denotes fractions to be highly variable across batches.Proteome Science 2007, 5:9 http://www.proteomesci.com/content/5/1/9
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was initially applied manually because of concerns with
pipetting such small volumes of highly volatile liquids.
However, there were several advantages to automated
application, including speed with which this could be per-
formed, and consistent drying times between applications
[13]. We also noticed a need to fine-tune spot protocols
for each ProteinChip-fraction combination so we defined
criteria based on intensity, S/N and resolution of few cho-
sen peaks [8]. This improved the number of peaks
detected and the reproducibility of the signal intensities.
By routinely performing and monitoring instrument
checks we have established criteria to detect changes in
instrument performance [8]. We added a spot-to-spot cor-
rection in Exp 2, but found it to have little impact on
results.
Comparison on the average peak intensity CVs from Exp
1 to Exp 2 showed a marked improvement, changes of 4%
to 37%. H50-F6 and IMAC-F3 did not show improve-
ment. This indicates that the experimental parameters
used in Exp 2 provided a considerable improvement in
spectral quality. Comparing our results to those of other
researchers is complicated due to different experimental
conditions – not all sera are fractionated, CVs not calcu-
lated for the QC sample alone, different ProteinChips, m/
z range differs for data collection, and/or peak selection
criteria varies. Koopman et al. [14] used a fractionated QC
serum to calculate intra-assay variation on 10 randomly
chosen peaks (S/N > 5, m/z < 20,000) and found a mean
CV = 24% for WCX-F1 (equivalent of CM10); 26% for
WCX-F6 and 29% for IMAC-F1. This compared to our
average CVs (from all batches) of 18, 25 and 23% respec-
tively for the whole spectrum (as opposed to selected
peaks). The QC serum serves as a good quality control for
assay and ProteinChip variability and it would be helpful
if all published SELDI data reported signal intensity CVs
of QC sera, with the criteria used for their calculation, so
more effective comparisons can be made across studies.
The mass accuracies in the two experiments were in
accordance with the manufacturer's specifications [9]. The
optimization of the acquisition protocols at the fraction
level (Exp 2) and automation of EAM application, have
substantially improved the reproducibility of peak inten-
sities.
We used a Kruskal-Wallis non-parametric test, with multi-
ple test correction to examine the variability of peak inten-
sities from the QC sera across the batches in which they
were run. Not surprisingly we found that several Protein-
Chip-fraction combinations had more variability than
others. Three ProteinChip-fractions had >30% of their
peak intensities being statistically different at p < 0.01
level (H50-F3, CM10-LS-F6, CM10-HS-F3). This indicates
that these may not be useful for biomarker discovery. This
analysis in Exp 1, showed very little statistical difference
Table 2: Summary table of results comparing Exp.1 and Exp.2 showing improvement in peak detection and peak intensity variation 
following optimization of protocols.
Experiment 1 Experiment 2
Protein 
Chip
Fraction No. 
Spectra 
excluded 
(Total 18)
No. 
Peaks
Averaged 
CV Peak 
Intensity (%)
CV 
Range
No. Peaks (%) 
statistically 
different 
across batches 
(p < 0.01)a
No. 
Spectra 
excluded 
(Total 18)
No. 
Peaks
Averaged 
CV Peak 
Intensity (%)
CV 
Range
No. Peaks 
statistically (%) 
different 
across batches 
(p < 0.01)a
F1 5 16 31.7 12–127 0 1 28 20.9 8–36 2 (7)
F3 1 11 31.2 15–75 0 0 21 31.4 12–52 2 (10)
IMAC F4 3 7 44.7 29–61 1 (14) 0 20 26.0 14–45 2 (10)
F6 3 21 27.0 15–39 0 7 27 22.6 11–49 9 (33)
LS-F1 4 22 31.0 15–50 0 1 23 18.1 11–41 1 (4)
LS-F3 6 5 41.5 25–48 0 0 23 26.4 13–40 3 (13)
LS-F4 1 13 37.4 18–55 6 (46) 1 26 14.7 8–30 0
CM10 LS-F5 4 9 30.6 20–46 3 (33) 0 27 16.4 8–30 1 (4)
LS-F6 3 13 29.4 18–44 0 2 30 25.4 8–50 11 (37)
HS-F3 6 3 66.5 53–85 0b 1 15 49.2 27–148 9 (60)
HS-F4 6 5 48.7 19–72 0 3 14 30.6 10–46 0
F1 5 6 67.5 40–129 0 0 16 32.7 15–66 2 (13)
F3 0 13 32.4 16–50 3 (23) 1 17 22.8 15–38 5 (29)
H50 F4 2 15 33.0 15–79 2 (15) 1 21 22.5 11–53 5 (24)
F6 2 30 23.7 13–39 1 (3) 1 35 25.0 12–55 3 (9)
a This column reports the number of peaks in the ProteinChip-fraction spectra that were considered to have different peak intensities between 
batches as calculated by the non-parametric Kruskal-Wallis (p < 0.01), the data was bootstrapped using 2000 randomizations of the experiments to 
correct for multiple testing.
b Analysis performed on 2 batches, not 3.Proteome Science 2007, 5:9 http://www.proteomesci.com/content/5/1/9
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between batches, which on the surface would imply better
data. However, on closer examination this is not true. The
spectra had fewer peaks, so less complexity and the vari-
ance was larger in each ProteinChip-fraction combina-
tion.  The analysis also pointed out good ProteinChip-
fraction combinations that would perform in the most
reproducible manner for biomarker discovery.
Conclusion
In this study, we have investigated the effects of some
practical factors for SELDI-TOF analysis of fractionated
serum samples. The analysis of 18 spectra (3 batches of
samples fractionated 2 weeks apart, 1 samples on each of
6 ProteinChips of one type) independently derived from
the same pooled serum sample allowed us to investigate
also the compounding effect of reproducibility over time.
Reproducibility of mass intensities relies on a high level of
standardization and optimization. Our study demon-
strates that optimized instrument settings and calibration
along with rigorous sample handling and processing can
almost double peak detection and substantially decrease
the peak intensity CVs. Nevertheless, we feel greater effort
is needed to improve peak detection and quantitation and
further investigation is needed to assess the reproducibil-
ity of the serum fractionation, looking to minimize varia-
tion when large sample numbers need to be processed.
Table 3: Differences in sample processing and analysis setting between Exp.1 and Exp.2
EAM application Acquisition protocol optimization Specimen applied for optimization Spot correction
Exp.1 Manual Chip specific Whole serum No
Exp.2 Automated Chip and Fraction specific Appropriate serum fraction QC Yes
Outline of the experimental workflow for SELDI-TOF optimization Figure 1
Outline of the experimental workflow for SELDI-TOF optimization. QC serum was fractionated and run as 6 replicates of frac-
tions F1, F3, F4, and F6 on IMAC, CM10 LS and H50 ProteinChips; as 6 replicates of F3 and F4 on CM10 HS and 6 replicates of 
F5 on CM10 LS ProteinChips.
As for Exp 1
QC Serum
Exp2
ProteinChip-Fraction optimized
Spot correction
Automated EAM addition
Batch 1
Fractionation, Week 0
Day1
F2 (pH7)
F1 (pH9)
Day 3
MS
F5 (pH3)
Day 11
MS
F4 (pH4)
Day 9
MS
F3 (pH5)
Day 5
MS
F6 (Organic)
Day 11
MS
Batch 3
Fractionation, Week 4
Day1
F2 (pH7)
F1 (pH9)
Day 3
MS
F5 (pH3)
Day 11
MS
F4 (pH4)
Day 9
MS
F3 (pH5)
Day 5
MS
F6 (Organic)
Day 11
MS
Batch 2
Fractionation, Week 2
Day1
F2 (pH7)
F1 (pH9)
Day 3
MS
F5 (pH3)
Day 11
MS
F4 (pH4)
Day 9
MS
F3 (pH5)
Day 5
MS
F6 (Organic)
Day 11
MS
Exp1
ProteinChip optimized
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Methods
Serum samples
A QC sample was prepared by pooling serum from 10
non-fasting anonymous donors (CDC Institutional
Review Board approval 1652), dispensed into single use
aliquots and stored at -80°C. This QC sample was frac-
tionated using the Biomek 2000 Automation Workstation
(Beckman Coulter) and the Expression Difference Map-
ping Kit-Serum Fractionation according to the manufac-
turer (Ciphergen). Six fractions were collected and stored
at -80°C for 2 to 11 days keeping storage time the same
for the equivalent fractions of each sample. The fractiona-
tion procedure was repeated on the same QC sample three
times with 2 weeks in between each fractionation. Each
fractionation procedure representing one batch (Fig. 1).
ProteinChips
To load the different ProteinChips, we used the corre-
spondent Biomek 2000 Automation Workstation meth-
ods. The IMAC 30 ProteinChip was loaded with copper
sulfate (Ciphergen Expression Difference Mapping kits
IMAC buffer), and H50 ProteinChip (Ciphergen Expres-
sion Difference Mapping kit-H50 buffer) was washed with
50% acetonitrile before being loaded with the serum frac-
tion. Except for these modifications, treatment of the Pro-
teinChips included two pre-washes of 150 μl of
corresponding buffer for 5 minutes each followed by
addition and 1 hour incubation on a microplate shaker of
100 μl sample (10 μl serum fraction in 90 μl of buffer).
Each protein chip had three 150 μl stringency washes fol-
lowed by 2 quick washes with 200 μl of HPLC water. One
binding-washing buffer was used for IMAC-Cu and H50
ProteinChips, and a low stringency (LS) and high strin-
gency (HS) binding-washing buffer was used for the
CM10 ProteinChip (resulting in 4 spectra for each serum
fraction). After the last wash, the ProteinChips were air-
dried for 20 minutes. The energy absorbing molecule
(EAM) was sinapinic acid (5 mg in 200 μl acetonitrile, 200
μl of 1% trifluoroacetic acid), which was freshly prepared
before a double application (1 ul each) to all Protein-
Chips with exactly 15 minutes drying time between each
application [6]. In Exp 1 the EAM was applied by hand
with a one-channel pipette. In the optimized method
(Exp 2) it was applied using the Biomek 2000 robot,
which dispensed 1 μL of EAM simultaneously to the eight
spots of a chip. The differences between the 2 experiment
protocols are outlined in Table 3. Mass analysis was per-
formed using a PBSIIc mass spectrometer over an m/z
range of 3000–30000.
Acquisition protocols
For both studies, we optimized the spot protocols using
the QC sample for the mass range between 3000 and
30000 Da. The major difference between Exp 1 and Exp 2
are the acquisition protocols. For Exp 1, spot protocols
were optimized for whole serum on each different Pro-
teinChip. To establish the optimized protocol different
laser intensities and detector sensitivities were used for the
collection of the spectra, and visual inspection used to
assess the best spectrum. These parameters were then used
in the spot protocol for experimental data acquisition. In
Exp 2, spot protocols were optimized for each serum frac-
tion-ProteinChip combination by adjusting laser intensity
and detector sensitivity. The spectra collected and proc-
essed using Ciphergen Express™ software (version 3) (CE).
All spectra normalized by total ion current and calibrated.
Peak detection performed using with peak height of 10
and valley depth of 5. Spectral quality was assessed using
2–3 randomly selected peaks by comparing peak inten-
sity, S/N and resolution. As Semmes et al. described [8],
the laser intensity and the detector sensitivity for the spot
protocol were chosen to increase the peak detection and
resolution without increasing the signal to noise ratio. The
optimized laser and detector sensitivity settings were used
in the appropriate spot protocols. We did not change the
detector voltage during the course of a study; but we
changed it between the 2 experiments after optimization
by DL Vary performance check as recommended by
Ciphergen Biosystems. In Exp 1 the mass spectra were
derived from 10 shots per transient, with a spacing of 5
between transients, acquiring a total of 130 laser shots for
each spectrum. This was after 2 warming shots not
included in the spectrum. In Exp 2, a total of 192 shots
were collected for each spectrum, from 12 transients every
4 positions after 2 warming shots not included in the
spectrum file.
Instrument performance evaluation
QC and performance checks included calibration and
alignment of the Biomek 2000 performed monthly. Mass
accuracy, resolution and sensitivity of the spectrometer
were evaluated monthly using the insulin standard chip
and the bovine IgG standard chip (Ciphergen). A normal
phase ProteinChip, NP20 (Ciphergen) was run weekly,
loaded with All-in-1 Protein standard II for external cali-
bration of the spectra. To minimize slight systematic shifts
in the time-of-flight data from one spot to another one,
we used the CE to calculate a spot-to-spot correction fac-
tor. The correction factor was calculated from 8 spectra
(One spectrum per spot position) of All-in-I Peptide
Standard (Ciphergen) on NP20 ProteinChip.
Data Analysis
All data were analyzed in CE. We applied baseline
smoothing before fitting the baseline using a moving
average filter window of 25 points, and an automatic fit-
ting width. We used an average filter of 0.2 times expected
peak width, to remove high frequency noise from the
spectrum improving the S/N. Spectral intensities were
normalized by total ion current and spectra with normal-Publish with BioMed Central    and   every 
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ization factor > 2SD were excluded. The spectra were cali-
brated from a weighted 3 parameter quadratic equation
calculated from 4 protein standards (mass range 7 to 30
kDa). Prior to alignment we did peak detection with set-
tings of peak height and valley depth at 6 times the noise.
Peak alignment was performed using the following set-
tings: 0.2% of mass window and minimum S/N of 5.
Peaks were identified using the CE Biomarker Analysis
Module Cluster Wizard according to these settings: first
pass S/N ≥ 3 and valley depth ≥ 3, minimum peak thresh-
old 80% of all spectra, preserving all 1st pass peaks, mass
window 0.2% of mass, second pass S/N ≥ 2 and valley
depth ≥ 2, add estimated peaks to complete clusters, auto-
centroid, and m/z range 3000–30000.
Calculations of average CVs for peak intensity were
accomplished in Microsoft Excel. Statistical analyses using
a non-parametric Kruskal-Wallis test, with a bootstrap of
2000 randomizations for multiple test correction, were
performed using Partek Genomics Suite (version 6.2 Cop-
yright © 2006).
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